Processa Pharma up as gastric disorder drug improves symptoms in study
14/12/2022 14:19
** Processa Pharmaceuticals Inc's shares PCSA.O up 11.6%
at $2.12 before the bell
** PCSA says its experimental drug to treat patients with
gastroparesis showed statistically significant improvement in
symptoms, when compared with placebo in mid-stage study
** The drug, PCS12852, was also well-tolerated
** Co says it plans to initiate its second mid-stage study
in 2023
** Gastroparesis is a disorder that slows or stops the
movement of food from your stomach to your small intestine, even
though there is no blockage in the stomach or intestines
** Up to Tuesday's close, stock was down ~66% YTD
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com;))